Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.52 |
| ▸ | MEN1 | O00255 | 4/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.45 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | DYRK1A | Q13627 | 4/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | MAPT | P10636 | 4/20 | 0.44 |
| ▸ | ATM | Q13315 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2280172 | 0.87 | KMT2A (0.54) | KMT2AMEN1CYP1A2POLBDYRK1A | |
| SCHEMBL15615933 | 0.87 | KMT2A (0.54) | KMT2AMEN1CYP1A2POLBDYRK1A | |
| SCHEMBL3786466 | 0.86 | TSHR (0.46) | KMT2AMEN1TSHRCYP1A2POLB | |
| SCHEMBL8326089 | 0.85 | KMT2A (0.52) | KMT2AMEN1CYP1A2POLBDYRK1A | |
| SCHEMBL8330280 | 0.85 | KMT2A (0.52) | KMT2AMEN1CYP1A2POLBDYRK1A | |
| SCHEMBL621738 | 0.84 | KMT2A (0.51) | KMT2AMEN1DYRK1AALDH1A1MAPT | |
| SCHEMBL4498553 | 0.81 | KMT2A (0.49) | KMT2AMEN1CYP1A2POLBDYRK1A | |
| SCHEMBL27783897 | 0.79 | KEAP1 (0.37) | KMT2AMEN1TSHRALDH1A1MAPT | |
| SCHEMBL9545028 | 0.79 | KMT2A (0.54) | KMT2AMEN1TSHRCYP1A2POLB | |
| SCHEMBL8327252 | 0.79 | CYP1A2 (0.55) | KMT2AMEN1CYP1A2POLBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2166853-B1 | THERAPEUTIC PYRAZOLONAPHTHYRIDINE DERIVATIVES | DART NEUROSCIENCE CAYMAN LTD (KY) | 2014-05-28 | — | — | EP | disclosed |
| EP-2166853-B1 | THERAPEUTIC PYRAZOLONAPHTHYRIDINE DERIVATIVES | DART NEUROSCIENCE CAYMAN LTD (KY) | 2014-05-28 | — | — | EP | disclosed |
| US-8497262-B2 | Therapeutic pyrazolonaphthyridine derivatives | DART NEUROSCIENCE (CAYMAN) LTD (KY) | 2013-07-30 | — | — | US | disclosed |
| US-8497262-B2 | Therapeutic pyrazolonaphthyridine derivatives | DART NEUROSCIENCE (CAYMAN) LTD (KY) | 2013-07-30 | — | — | US | disclosed |
| US-8497262-B2 | Therapeutic pyrazolonaphthyridine derivatives | DART NEUROSCIENCE (CAYMAN) LTD (KY) | 2013-07-30 | — | — | US | disclosed |
| US-20110065692-A1 | THERAPEUTIC PYRAZOLONAPHTHYRIDINE DERIVATIVES | HELICON THERAPEUTICS, INC. (US) | 2011-03-17 | — | — | US | disclosed |
| US-20110065692-A1 | THERAPEUTIC PYRAZOLONAPHTHYRIDINE DERIVATIVES | HELICON THERAPEUTICS, INC. (US) | 2011-03-17 | — | — | US | disclosed |
| US-20110065692-A1 | THERAPEUTIC PYRAZOLONAPHTHYRIDINE DERIVATIVES | HELICON THERAPEUTICS, INC. (US) | 2011-03-17 | — | — | US | disclosed |
| US-7858614-B2 | Therapeutic pyrazolonaphthyridine derivatives | HELICON THERAPEUTICS, INC. (US) | 2010-12-28 | — | — | US | disclosed |
| US-7858614-B2 | Therapeutic pyrazolonaphthyridine derivatives | HELICON THERAPEUTICS, INC. (US) | 2010-12-28 | — | — | US | disclosed |
| US-7858614-B2 | Therapeutic pyrazolonaphthyridine derivatives | HELICON THERAPEUTICS, INC. (US) | 2010-12-28 | — | — | US | disclosed |
| EP-2166853-A1 | THERAPEUTIC PYRAZOLONAPHTHYRIDINE DERIVATIVES | Helicon Therapeutics, Inc. (US) | 2010-03-31 | — | — | EP | disclosed |
| US-20090005365-A1 | THERAPEUTIC PYRAZOLONAPHTHYRIDINE DERIVATIVES | HELICON THERAPEUTICS, INC. (US) | 2009-01-01 | — | — | US | disclosed |
| US-20090005365-A1 | THERAPEUTIC PYRAZOLONAPHTHYRIDINE DERIVATIVES | HELICON THERAPEUTICS, INC. (US) | 2009-01-01 | — | — | US | disclosed |
| US-20090005365-A1 | THERAPEUTIC PYRAZOLONAPHTHYRIDINE DERIVATIVES | HELICON THERAPEUTICS, INC. (US) | 2009-01-01 | — | — | US | disclosed |
| WO-2008154447-A1 | THERAPEUTIC PYRAZOLONAPHTHYRIDINE DERIVATIVES | HELICON THERAPEUTICS, INC. (US) | 2008-12-18 | — | — | WO | disclosed |
| WO-2008154447-A1 | THERAPEUTIC PYRAZOLONAPHTHYRIDINE DERIVATIVES | HELICON THERAPEUTICS, INC. (US) | 2008-12-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110065692-A1 | THERAPEUTIC PYRAZOLONAPHTHYRIDINE DERIVATIVES | GABRA5, GABRA4, GABRA1 | KMT2A 3524/4885MEN1 4169/4885TSHR 223/4885 |
| US-20090005365-A1 | THERAPEUTIC PYRAZOLONAPHTHYRIDINE DERIVATIVES | GABRA5, GABRA4, GABRA1 | KMT2A 3524/4885MEN1 4169/4885TSHR 223/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.